Abstract
A metabolically stable and centrally acting analog of pGlu-Glu-Pro-NH2 ([Glu2]TRH, a tripeptide structurally related to TRH (thyrotropin-releasing hormone)) was designed by replacing the amino-terminal pyroglutamyl residue with a pyridinium moiety. The analeptic action of the analog was used to optimize the efficacy of this novel CNS agent when administered intravenously in its CNS-permeable prodrug forms obtained via the reduction of the pyridinium moiety to the nonionic dihydropyridine and esterifying the central Glu with various alcohols. The maximum effect in antagonizing pentobarbital-induced narcosis in mice was achieved with the hexyl ester that was used subsequently for a comparative evaluation with a prodrug of the parent neuropeptide in the Porsolt swim test as a paradigm for antidepressant effect. The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety.
Keywords: [glu2]trh, central nervous system permeable prodrugs, analeptic effect, antidepressant, porsolt swim test, immobilized artificial membrane chromatography
Medicinal Chemistry
Title: A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents
Volume: 1 Issue: 2
Author(s): K. Prokai-Tatrai, M. Teixido, V. Nguyen, A. D. Zharikova and L. Prokai
Affiliation:
Keywords: [glu2]trh, central nervous system permeable prodrugs, analeptic effect, antidepressant, porsolt swim test, immobilized artificial membrane chromatography
Abstract: A metabolically stable and centrally acting analog of pGlu-Glu-Pro-NH2 ([Glu2]TRH, a tripeptide structurally related to TRH (thyrotropin-releasing hormone)) was designed by replacing the amino-terminal pyroglutamyl residue with a pyridinium moiety. The analeptic action of the analog was used to optimize the efficacy of this novel CNS agent when administered intravenously in its CNS-permeable prodrug forms obtained via the reduction of the pyridinium moiety to the nonionic dihydropyridine and esterifying the central Glu with various alcohols. The maximum effect in antagonizing pentobarbital-induced narcosis in mice was achieved with the hexyl ester that was used subsequently for a comparative evaluation with a prodrug of the parent neuropeptide in the Porsolt swim test as a paradigm for antidepressant effect. The novel analog maintained its antidepressant potency but showed reduced analeptic action compared to [Glu2]TRH; thus, an increase in the selectivity of CNS-action was obtained by the incorporation of the pyridinium moiety.
Export Options
About this article
Cite this article as:
Prokai-Tatrai K., Teixido M., Nguyen V., Zharikova D. A. and Prokai L., A Pyridinium-substituted Analog of the TRH-like Tripeptide pGlu-Glu- Pro-NH2 and its Prodrugs as Central Nervous System Agents, Medicinal Chemistry 2005; 1 (2) . https://dx.doi.org/10.2174/1573406053175256
DOI https://dx.doi.org/10.2174/1573406053175256 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Developments in Peroxidation of Polyunsaturated Fatty Acids
Letters in Organic Chemistry Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Mass Spectrometry-Based Approaches Toward Absolute Quantitative Proteomics
Current Genomics Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Current Study on the Development of Bis-pyridinium Oxime Reactivators for the Antidotal Treatment of Poisoning by Toxic Organophosphorus Agents
Current Organic Chemistry Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Meet Our Editorial Board Member:
Current Alzheimer Research Kinetics of Amyloid and Prion Fibril Formation in the Absence and Presence of Dense Shell Sugar-Decorated Dendrimers
Current Medicinal Chemistry Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Overlapping the Tryptophan Catabolite (TRYCAT) and Melatoninergic Pathways in Alzheimer's Disease
Current Pharmaceutical Design Review of Pediatric Uveitis
Current Pediatric Reviews Food Addiction and Neuroimaging
Current Pharmaceutical Design Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design 4q21.2q21.3 Duplication: Molecular and Neuropsychological Aspects
Current Genomics Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Current Outcomes and Future Perspectives of Cochlear Implants
Current Drug Therapy Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Current Neuropharmacology Advances of Molecular Imaging Probes for the Diagnosis of Alzheimer's Disease
Current Alzheimer Research